Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.35 |
| ▸ | ESR1 | P03372 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.33 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037758 | 0.81 | KDM4E (0.42) | KDM4EALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL2146781 | 0.79 | ALDH1A1 (0.37) | ALDH1A1LMNAMEN1KMT2AESR2 | |
| SCHEMBL1039147 | 0.78 | ALDH1A1 (0.49) | KDM4EALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL1077603 | 0.78 | KDM4E (0.40) | KDM4EALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL2146463 | 0.77 | ESR2 (0.35) | KDM4EALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL2146468 | 0.77 | ESR2 (0.35) | KDM4EALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL1077691 | 0.77 | CYP11B2 (0.45) | KDM4EALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL1074336 | 0.76 | KDM4E (0.39) | KDM4EALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL12415295 | 0.74 | MEN1 (0.33) | KDM4EALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL1078178 | 0.74 | KDM4E (0.40) | KDM4EALDH1A1LMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974776-B2 | Estrogen receptor beta agonists for use in treating mesothelioma | OASMIA PHARMACEUTICAL AB (SE) | 2018-05-22 | — | — | US | claimed |
| US-20160303087-A1 | Estrogen Receptor Beta Agonists for Use in Treating Mesothelioma | OASMIA PHARMACEUTICAL AB (SE) | 2016-10-20 | — | — | US | claimed |
| EP-3076964-A1 | ESTROGEN RECEPTOR BETA AGONISTS FOR USE IN TREATING MESOTHELIOMA | Karo Pharma AB (SE) | 2016-10-12 | — | — | EP | claimed |
| CN-105960236-A | Estrogen receptor beta agonists for use in treating mesothelioma | 卡罗医药股份公司 | 2016-09-21 | — | — | CN | claimed |
| WO-2016050945-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING ESTROGEN RECEPTOR-BETA AGONISTS WITH PLATINUM DRUGS OR PACLITAXEL FOR TREATING OVARIAN CANCER | KARO BIO AB (SE) | 2016-04-07 | — | — | WO | claimed |
| WO-2015082643-A1 | ESTROGEN RECEPTOR BETA AGONISTS FOR USE IN TREATING MESOTHELIOMA | KARO BIO AB (SE) | 2015-06-11 | — | — | WO | claimed |
| EP-2276732-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KAROBIO AB (SE) | 2015-05-20 | — | — | EP | claimed |
| CN-102066323-B | Novel estrogen receptor ligands | KAROBIO AB | 2015-05-13 | — | — | CN | claimed |
| US-8653072-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2014-02-18 | — | — | US | claimed |
| US-20130131061-A1 | Novel Estrogen Receptor Ligands | KARO BIO AB (SE) | 2013-05-23 | — | — | US | claimed |
| US-8367665-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2013-02-05 | — | — | US | claimed |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | OASMIA PHARMACEUTICAL AB (SE) | 2011-08-04 | — | — | US | claimed |
| CN-102066323-A | Novel estrogen receptor ligands | KAROBIO AB | 2011-05-18 | — | — | CN | claimed |
| EP-2276732-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-01-26 | — | — | EP | claimed |
| WO-2009127686-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-10-22 | — | — | WO | claimed |
| US-9974776-B2 | Estrogen receptor beta agonists for use in treating mesothelioma | OASMIA PHARMACEUTICAL AB (SE) | 2018-05-22 | — | — | US | disclosed |
| US-20160303087-A1 | Estrogen Receptor Beta Agonists for Use in Treating Mesothelioma | OASMIA PHARMACEUTICAL AB (SE) | 2016-10-20 | — | — | US | disclosed |
| US-8367665-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | OASMIA PHARMACEUTICAL AB (SE) | 2011-08-04 | — | — | US | disclosed |
| CN-102066323-A | Novel estrogen receptor ligands | KAROBIO AB | 2011-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303087-A1 | Estrogen Receptor Beta Agonists for Use in Treating Mesothelioma | GPER1, ESR2, ESRRG | KDM4E 389/4885ALDH1A1 1632/4885LMNA 840/4885 |
| US-20130131061-A1 | Novel Estrogen Receptor Ligands | ESR1, GPER1, ESRRA | KDM4E 405/4885ALDH1A1 1765/4885LMNA 3927/4885 |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, GPER1, ESRRA | KDM4E 379/4885ALDH1A1 1909/4885LMNA 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.